1	Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the
2	VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan
3	
4	Mayu Nagura-Ikeda ^a , Kazuo Imai ^{a, b} *, Katsumi Kubota ^c , Sakiko Noguchi ^c ,
5	Yutaro Kitagawa ^c , Masaru Matsuoka ^c , Sakiko Tabata ^a , Kazuyasu Miyoshi ^a , Toshimitsu Ito ^a ,
6	Kaku Tamura ^a , Takuya Maeda ^c
7	
8	a) Self-Defense Forces Central Hospital, Tokyo, Japan
9	b) Department of Infectious Disease and Infection Control, Saitama Medical University,
10	Saitama, Japan
11	c) Department of Clinical Laboratory, Saitama Medical University, Saitama, Japan
12	
13	
14	*Corresponding author:
15	Kazuo Imai, M.D.,
16	Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo 154-0001, Japan
17	E-mail: k_imai@saitama-med.ac.jp
18	Tel: +81-3-3411-0151
19	
20	Key words: SARS-CoV-2, COVID-19, Antibody, Chemiluminescent immunoassay, Japan
21	
22	Running title: Evaluation of antibody tests for COVID-19
23	

24 Abstract

25	Background: We evaluated clinical characteristics and the clinical utility of VITROS
26	SARS-CoV-2 antibody tests according to COVID-19 severity in patients in Japan.
27	Methods: We analyzed 255 serum specimens from 130 COVID-19 patients and examined
28	clinical records and laboratory data. Presence of total (IgA, IgM, and IgG) and specific IgG
29	antibody for the spike 1 antigen of SARS-CoV2 was determined using VITROS
30	Anti-SARS-CoV-2 antibody tests.
31	Findings: Overall, 98 (75.4%) and 32 (24.6%) patients had mild and severe COVID-19,
32	respectively. On admission, 76 (58.5%) and 45 (34.6%) patients were positive for total and
33	IgG antibody assays. Among 91 patients at discharge, 90 (98.9%) and 81 (89.0%) patients
34	were positive for total and IgG antibody, respectively. Clinical background and laboratory
35	findings on admission, but not the prevalence or concentration of total or IgG antibody, were
36	associated with disease prognosis. Total and IgG antibody intensity were significantly higher
37	in severe cases than in mild cases in serum collected after 11 days from onset, but not within
38	10 days.
39	Conclusion: VITROS Anti-SARS-CoV-2 Total and IgG assays will be useful as supporting
40	diagnostic and surveillance tools and for evaluation of humoral immune response to

41 COVID-19. Clinical background and laboratory findings are preferable predictors of disease
 42 prognosis.

43

44 Introduction

45	The novel coronavirus disease 2019 (COVID-19), which is caused by severe acute
46	respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, was initially reported in
47	December 2019 in Wuhan, China [1], and it has since gained pandemic status worldwide [2].
48	Serological tests are important because they provide faster results for surveillance and they
49	support diagnosis based on the gold standard method of quantitative reverse-transcription
50	polymerase chain reaction (RT-qPCR) [3]. Additionally, several reports have suggested that
51	the antibody response to SARS-CoV-2 could be associated with disease severity [4-11].
52	Therefore, investigating this response in COVID-19 patients is important in order to assess
53	the clinical utility of serological assays as supporting diagnostic tools and to understand the
54	pathogenicity of SARS-CoV-2.
55	The serological tests currently available to detect total, IgM, and IgG antibodies against
56	SARS-CoV-2 include enzyme-linked immunosorbent assay (ELISA),
57	immunochromatography assay, and chemiluminescence immunoassay (CLIA) [12-15]. In
58	particular, CLIA is widely used for COVID-19 detection in clinical settings because it is a
59	rapid, high-throughput, and semi-quantitative method for detecting antibodies that is easy to
60	perform. Commercial serological assays use a variety of SARS-CoV-2 antigens, including
61	internal nucleocapsid protein (NP) and external spike (S) proteins. The S protein is composed
62	of two subunits, S1 and S2. S1 contains the receptor binding domain (RBD), which is
63	responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor on the host
64	cells at initiation of infection [16]. RBD is considered the major epitope recognized by
65	SARS-CoV-2 neutralization antibodies [11, 17, 18]. Therefore, CLIA kits using S1 antigen are
66	expected to be used both for diagnostic support and for the assessment of humoral immunity
67	against SARS-CoV-2. The VITROS Anti-SARS-CoV-2 Total Antibody Test and VITROS
68	Anti-SARS-CoV-2 IgG Antibody Test (Ortho Clinical Diagnostics, Raritan, NJ) both use the

69 S1 protein of SARS-COV-2 and have been approved by the US Food and Drug

70 Administration as commercial CLIAs for SARS-CoV-2 [19]. However, the clinical utility of

these two antibody assays for COVID-19 and differences in antibody response in association

with disease severity have not been well evaluated [20].

Here, we describe the clinical characteristics of patients with COVID-19 in Japan and report the clinical performance of and antibody response to the VITROS Anti-SARS-CoV-2 antibody assays for total (IgA, IgM, and IgG) and specific IgG antibodies to S1 protein of SARS-CoV-2, assessed in 255 serum samples collected from 130 COVID-19 patients with differing disease severity.

78

79 Methods

80 Patients with COVID-19 and serum samples

81 This study included 130 patients with COVID-19 who were referred to the 82 Self-Defense Forces Central Hospital, a designated medical institution for specific infectious 83 diseases in Tokyo, Japan, from February 26 to May 8, 2020. All were confirmed to have COVID-19 infection by RT-qPCR for SARS-CoV-2 according to the nationally recommended 84 85 protocol [21]. We retrospectively collected patient information from electronic medical 86 records. Serum samples were collected on the day of admission and during hospitalization. 87 All serum samples were stored at -80° C before use in the antibody tests. This study was reviewed and approved by the Self-Defense Forces Central Hospital (approval number 88 89 01-011), and Saitama Medical University (approval number 917). Written informed consent 90 was obtained from enrolled patient.

91

92 Detection of antibodies for SARS-CoV-2

93	Total and IgG antibody assays against SARS-CoV-2 S proteins were performed using
94	the VITROS Anti-SARS-CoV-2 Total Antibody Test and VITROS Anti-SARS-CoV-2 IgG
95	Antibody Test (Ortho Clinical Diagnostics) according to the manufacturer's instructions.
96	Results were interpreted in accordance with these instructions as positive (signal for test
97	sample /signal at cutoff [S/CO] \geq 1.00) or negative (S/CO < 1.0) for both total and IgG
98	assays.
99	
100	Definition of cases
101	Symptomatic cases were then subdivided into severe and mild groups. Severe
102	symptomatic cases were defined as patients with clinical symptoms of pneumonia (saturation
103	of percutaneous oxygen [SpO ₂] <93% and need for oxygen therapy). Other symptomatic
104	cases were classified as mild. The criterion for discharging COVID-19 patients from hospital
105	was a negative result on two consecutive RT-qPCR tests [21] using throat swab specimens
106	under the Infectious Disease Control Law in effect from February 11 to May 13, 2020.
107	
108	Statistical analysis
109	Continuous variables are expressed as the mean \pm standard deviation (SD) or
110	median interquartile range [IQR] and were compared using the t-test or Wilcoxon Rank Sum
111	test for parametric or non-parametric data, respectively. Categorical variables are expressed as
112	number (%) and were compared using the $\chi 2$ test or Fisher's exact test. All statistical analyses
113	were performed using R (v 4.0.0; R Foundation for Statistical Computing, Vienna, Austria
114	[http://www.R-project.org/]).
115	
116	Results

117 Clinical characteristics of patients with COVID-19 in Japan

118	Table 1 shows the baseline clinical characteristics of all 130 patients. Briefly, the
119	patients ranged in age from 18 to 91 years (median, 45 years; IQR, 37-59 years); 77 (59.2%)
120	were male and 53 (40.8%) were female. The time from symptom onset to admission day was
121	3–21 days (median, 8 days; IQR, 6–10 days). Among the 66 (50.8%) patients who had
122	underlying diseases, hypertension (17.7%) and respiratory disorder (17.7%) were most
123	frequently observed. The most common clinical features on admission were fever (91.5%)
124	and cough (53.1%). Furthermore, 76 (58.5%) and 45 (34.6%) patients were positive for total
125	and IgG antibody assay, respectively, on admission. In total, 126 (96.9%) patients recovered
126	and were discharged from hospital, and 4 (3.1%) patients died during the observation period.
127	The median duration from initial symptom onset to confirmatory twice-negative PCR for
128	SARS-CoV-2 RNA was 17 days (IQR 14-22 days). Also, 32 (24.6%) patients required
129	supplemental oxygen therapy and were classified as having severe COVID-19. The medium
130	period from symptom onset to requiring supplemental oxygen therapy was 9 days (IQR 7-11
131	days). Among the 32 severe cases, high-flow nasal cannula therapy was required in 14
132	(10.8%) and mechanical ventilation was required in 5 (3.8%).
133	Univariate analysis revealed that age ($p < 0.001$) and male preponderance ($p = 0.002$)
134	were significantly higher in the severe COVID-19 group than in the mild COVID-19 group.
135	The prevalence of underlying disease was also higher in severe cases ($p < 0.001$), with
136	significant differences especially in the prevalence of hypertension ($p < 0.001$), diabetes
137	mellitus ($p = 0.013$), and malignancy ($p = 0.014$). There were no significant differences in
138	clinical features between the two groups. Blood test results revealed severe cases had higher
139	concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate
140	dehydrogenase (LDH), and C-reactive protein (CRP), higher white blood cell count and
141	neutrophil/lymphocyte ratio (NLR), and lower sodium level and lymphocyte count than mild
142	cases. There were no significant differences in the positivity rate or S/CO for either total or

143 IgG antibody assay on admission between the two groups.

All 91 patients had paired serum samples, collected on admission and discharge (Table 2), and among them on discharge, 90 (98.9%) and 81 (89.0%) patients were positive for total and IgG antibody, respectively. The S/CO of total and IgG antibody on discharge was significantly higher in severe cases than in mild cases (p < 0.001 for total and p = 0.009 for IgG antibodies), while there was no significant difference in the seropositive rate for either total or IgG antibody between the two groups on discharge (p > 0.05).

150

151 Comparison of antibody response in COVID-19 patients

152For the 255 collected serum specimens obtained from 130 patients, the period from 153 initial symptom onset to sample collection was 1–49 (median 13 days, IQR 9-18). Among the 154 serum specimens, the positivity rate for total and IgG increased with longer clinical course, 155 and total antibody was detected earlier than specific IgG antibody (Figure 1). In mild and 156 severe cases, total antibody assay was positive in 54.4% (37/68) and 47.8% (11/23) of 157 specimens collected within 10 days of onset, in 95.6% (86/90) and 100% (28/28) collected 158 within 11–20 days, and 100% (23/23) and 100% (23/23) collected >21 days after onset, 159 respectively. The corresponding detection rates for IgG antibody were 25.0% (17/68) and 160 26.1% (6/23), 75.6% (68/90) and 89.3% (25/28), and 100% (23/23) and 100% (23/23). There 161 was no significant difference in the prevalence of total or IgG antibody positivity between 162 severe and mild cases (p > 0.05). Among the 130 patients, 3 serum samples collected from 2 163 patients were negative for total antibody but positive for IgG antibody. Among both mild and 164 severe cases, S/CO also increased with a longer clinical course (Figure 2). S/CO for the total 165 and IgG antibody assays was significantly higher in severe cases than in mild cases among 166 serum samples collected from patients 11-20 days after onset (p < 0.001 for both total and 167 IgG antibodies) and >21 days after onset (p = 0.039 for total and p < 0.001 for IgG antibodies), but there was no significant difference within 10 days (p > 0.05 for both total and IgG antibodies; Figure 3).

170

171 Discussion

172	Here, we have presented the clinical characteristics of patients with COVID-19 in
173	Japan and provided evidence for the clinical utility of the VITROS Anti-SARS-CoV-2 Total
174	and IgG assays in diagnosing COVID-19 as well as for differences in antibody response
175	against the SARS-CoV-2 S1 protein with regard to disease severity.
176	Total antibody (IgA, IgM, and IgG) for SARS-CoV-2 S1 protein was detected earlier
177	than IgG antibody, and therefore total antibody assays appear to be preferable for initial
178	diagnostic testing for COVID-19 in patients who develop symptoms within 2 weeks. The
179	sensitivity of the total antibody assay was 47.8-54.4% and 95.6-100% in serum collected
180	within 10 days and >11 days from onset, respectively. This finding was consistent with
181	previous reports, which showed rapidly increased detection of IgA, IgM, and IgG antibodies
182	against S protein from day 10-15 after onset based on ELISA [22, 23], and other commercial
183	CLIA kits that used the NP or S1+2 protein as an antigen [24-26]. In this study, we
184	demonstrated that disease severity did not affect the positivity rate of the VITROS
185	Anti-SARS-CoV-2 Total antibody assay. Therefore, the total antibody assay will be useful in
186	clinical settings as a supporting diagnostic tool alongside the gold standard RT-qPCR for both
187	mild and severe cases.
188	Regarding the timing of discharge with negative viral RNA results from throat swab
189	specimens, the positivity rate for total and IgG antibodies was 98.9% and 89.0%, respectively.
190	Additionally, almost 100% of serum samples were positive for total and IgG antibodies in the
191	late phase of the clinical course (>21 days) in both mild and severe cases. Generally, both IgA

and IgM antibodies have a relatively shorter lifespan than IgG antibody. Also, IgA antibody

for S1 protein is reported to be less specific than IgG [11]. Taken together, the IgG antibody
assay is preferable to the total antibody assay for surveillance of COVID-19 seroprevalence.
Liu et al. reported a strong correlation of the IgG titer against S1 with the RBD. [27] Although
further study is still needed to clarify the correlation of antibody titer determined by the
VITROS Anti-SARS-CoV-2 antibody assays and neutralization antibody, the weight of
evidence to date suggests that the VITROS Anti-SARS-CoV-2 antibody assays also may be
used for the evaluation of humoral immunity against SARS-CoV-2.

200 In terms of the discrepancy in antibody response to S protein with regard to severity, 201 Zhao et al. reported a significantly higher antibody titer for S protein in severe cases than mild 202 cases based on ELISA [22]. Our findings of higher S/CO for both the total and IgG antibody 203 assays in severe cases in serum collected after 11 days from symptom onset are consistent 204 with theirs. However, antibody titer within 10 days after onset or on the day of admission did 205 not differ significantly according to disease severity. In our study, median time from symptom 206 onset to admission and time from onset to need for oxygen therapy was 8 and 9 days, 207 respectively. Thus, antibody titer may be an indicator of disease severity, but it may not be a 208 predictor of prognosis in the early phase. In this study, clinical background (distribution of 209 age, sex, and underlying disease) and laboratory findings (AST, ALT, LDH, CRP, sodium, 210 WBC count, lymphocyte count, and NLR) on admission were associated with disease 211 prognosis, as reported previously [28-32]. Therefore, it is preferable to use these clinical 212 background characteristics and laboratory findings as predictors of disease prognosis in the 213 early phase of the clinical course.

This study has some limitations. First, despite the confirmed high specificity of VITROS Anti-SARS-CoV-2 antibody assays [19, 20], specificity should be further analyzed using clinical specimens from non-COVID-19 patients. Also, recent reports showed a time-dependent decrease in antibody titer after the initial infection, especially in

218	asymptomatic and mild cases [33]. Further studies are warranted to determine the utility of
219	VITROS Anti-SARS-CoV-2 antibody assays as diagnostic and surveillance tools for
220	COVID-19.
221	
222	Conclusion
223	The qualitative results of the VITROS Anti-SARS-CoV-2 Total and IgG assays are
224	useful, as are their S/CO values in supporting diagnosis and surveillance in both mild and
225	severe COVID-19 cases. There are differences in antibody response to SARS-CoV-2 S1
226	protein according to disease severity, and thus clinical background characteristics and
227	laboratory findings are preferable predictors of disease prognosis in the early phase of the
228	clinical course.
229	
230	References
231	[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infecte
231 232	[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infecte with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO
231 232 233	[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infecte with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5.
231 232 233 234	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO: 10.1016/S0140-6736(20)30183-5. [2] World Health Organization
231 232 233 234 235	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accessed accessed in the second sec
231 232 233 234 235 236	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accessed 14/Jul/2020]
231 232 233 234 235 236 237	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accessed 14/Jul/2020] [3] Winter AK, Hegde ST. The important role of serology for COVID-19 control. The Lanced 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5.
231 232 233 234 235 236 237 238	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DOI 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accessed 14/Jul/2020] [3] Winter AK, Hegde ST. The important role of serology for COVID-19 control. The Lanced Infectious Diseases. 2020;20:758-759. DOI: 10.1016/S1473-3099(20)30322-4.
231 232 233 234 235 236 237 238 239	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accessed 14/Jul/2020] [3] Winter AK, Hegde ST. The important role of serology for COVID-19 control. The Lanced Infectious Diseases. 2020;20:758-759. DOI: 10.1016/S1473-3099(20)30322-4. [4] Shen L, Wang C, Zhao J, Tang X, Shen Y, Lu M, et al. Delayed specific IgM antibod
231 232 233 234 235 236 237 238 239 240	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accessed 14/Jul/2020] [3] Winter AK, Hegde ST. The important role of serology for COVID-19 control. The Lanced Infectious Diseases. 2020;20:758-759. DOI: 10.1016/S1473-3099(20)30322-4. [4] Shen L, Wang C, Zhao J, Tang X, Shen Y, Lu M, et al. Delayed specific IgM antibod responses observed among COVID-19 patients with severe progression. Emerging Microbed
231 232 233 234 235 236 237 238 239 240 241	 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infecter with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506. DO 10.1016/S0140-6736(20)30183-5. [2] World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Latest accesser 14/Jul/2020] [3] Winter AK, Hegde ST. The important role of serology for COVID-19 control. The Lancet Infectious Diseases. 2020;20:758-759. DOI: 10.1016/S1473-3099(20)30322-4. [4] Shen L, Wang C, Zhao J, Tang X, Shen Y, Lu M, et al. Delayed specific IgM antibod responses observed among COVID-19 patients with severe progression. Emerging Microbe & Infections. 2020;9:1096-101. DOI: 10.1080/22221751.2020.1766382.

- IgM and IgG responses in COVID-19 patients. Emerging Microbes & Infections.
 2020;9:940-8. DOI: 10.1080/22221751.2020.1762515.
- [6] Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies against
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases.
- 247 2020. DOI: 10.1093/cid/ciaa489
- 248 [7] Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z, et al. Characteristics of patients with
- coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. Journal of
- 250 Medical Virology. 2020. DOI: 10.1002/jmv.25930
- [8] Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG
- antibodies in patients with coronavirus disease 2019. Clinical & Translational Immunology.
- 253 2020;9:e01136. DOI: 10.1002/cti2.1136
- [9] To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral
- load in posterior oropharyngeal saliva samples and serum antibody responses during infection
- by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases.
 2020;20:565-74. DOI: 10.1016/S1473-3099(20)30196-1.
- [10] Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro
- 260 Surveillance. 2020;25. DOI: 10.2807/1560-7917.ES.2020.25.16.2000421
- [11] Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe
- 262 Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus
- 263 Disease Patients. Emerging Infectious Diseases. 2020;26:1478-88. DOI:
 264 10.3201/eid2607.200841
- [12] Yong SEF, Anderson DE, Wei WE, Pang J, Chia WN, Tan CW, et al. Connecting clusters
- of COVID-19: an epidemiological and serological investigation. The Lancet Infectious
- 267 Diseases. 2020;20:809-815. DOI: 10.1016/S1473-3099(20)30273-5

- [13] Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance
- 269 Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise,
- Idaho. Journal of Clinical Microbiology. 2020. DOI: 10.1128/JCM.00941-20.
- [14] Pan Y, Li X, Yang G, Fan J, Tang Y, Zhao J, et al. Serological immunochromatographic
- approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. Journal of Infection.
- 273 2020;81:e28-e32. DOI: 10.1016/j.jinf.2020.03.051.
- [15] Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six
- 275 high-throughput SARS-CoV-2 IgG antibody assays. Journal of Clinical Virology.
- 276 2020;129:104480. DOI: 10.1016/j.jcv.2020.104480.
- [16] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function,
- and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281-92.e6. DOI:
 10.1016/j.cell.2020.02.058.
- [17] Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al.
- 281 The receptor binding domain of the viral spike protein is an immunodominant and highly
- specific target of antibodies in SARS-CoV-2 patients. Science Immunology. 2020;5:eabc8413.
- 283 DOI: 10.1126/sciimmunol.abc8413.
- [18] Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al.
- A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine. 2020.
- 286 26:1033-1036. DOI: 10.1038/s41591-020-0913-5.
- [19] U.S. Food and Drug Administration. EUA Authorized Serology Test Performance.
- 288 https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-s
- erology-test-performance. [Latest accessed 14/Jul/2020]
- 290 [20] Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four
- 291 High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2.
- Journal of Clinical Microbiology. 2020. DOI: 10.1128/JCM.01243-20.

- [21] Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of Genetic
- Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. Japanese Journal of
 Infectious Diseases. 2020. DOI: 10.7883/yoken.JJID.2020.061.
- 296 [22] Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to
- 297 SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases.
- 298 2020. DOI: 10.1093/cid/ciaa344.
- [23] Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and
- 300 Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against
- 301 SARS-CoV-2. Journal of Clinical Microbiology. 2020;58:e00461-20. DOI:
 302 10.1128/JCM.00461-20.
- 303 [24] Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubée V, et al. Assessment of
- 304 SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three
- 305 immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral
- flow immunoassay (NG Biotech). Journal of Clinical Virology. 2020;129:104511. DOI:
 10.1016/j.jcv.2020.104511.
- 308 [25] Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four
 309 High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2.
 310 Journal of clinical microbiology. 2020. DOI: 10.1128/JCM.01243-20.
- [26] Egger M, Bundschuh C, Wiesinger K, Gabriel C, Clodi M, Mueller T, et al. Comparison
 of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDITM enzyme linked
 immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clinica
 Chimica Acta. 2020;509:18-21. DOI: 10.1016/j.cca.2020.05.049.
- [27] Liu T, Hsiung J, Zhao S, Kost J, Sreedhar D, Olson K, et al. High-Accuracy Multiplexed
 SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic
 Platform. bioRxiv. 2020:2020.06.16.155580. DOI: https://doi.org/10.1101/2020.06.16.155580

- [28] Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts
- critical illness patients with 2019 coronavirus disease in the early stage. Journal of
 Translational Medicine. 2020;18:206. DOI: 10.1186/s12967-020-02374-0.
- [29] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
 Lancet. 2020;395:1054-62. DOI: 10.1016/S0140-6736(20)30566-3.
- 324 [30] Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, et al. Clinical
- 325 characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond
- Princess cruise ship: a retrospective analysis. The Lancet Infectious Diseases. 2020. DOI:
- 327 10.1016/S1473-3099(20)30482-5.
- [31] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality
- in adult COVID-19 inpatients in Wuhan. The Journal of Allergy and Clinical Immunology.
- 330 2020;146:110-8. DOI: 10.1016/j.jaci.2020.04.006.
- [32] Wang Y, Shi L, Wang Y, Yang H. An updated meta-analysis of AST and ALT levels and
 the mortality of COVID-19 patients. American Journal of Emergency Medicine.
 2020:S0735-6757:30426-5. DOI: 10.1016/j.ajem.2020.05.063.
- [33] Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological
- assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine. 2020. DOI:
- 336 10.1038/s41591-020-0965-6.
- 337

338 **Conflict of interest**

- 339
- The authors declare that they have no conflicts of interest.
- 340

341 Funding

342	This research did not receive any specific grant from funding agencies in the public,
343	commercial, or nonprofit sectors.
344	
345	Acknowledgments
346	We thank the clinical laboratory technicians at the Self-Defense Forces Central Hospital
347	for sample collection, and all members of the COVID-19 Task Force at the Self-Defense
348	Forces Central Hospital and participating members drawn from other institutes of the Japan
349	Self-Defense Forces.
350	
351	Authors' contributions
352	TM and KI: study conception and design; MNI, KI, and ST: clinical data collection and
353	data analysis; SN, YK, and MM: experiment data analysis; MNI, KI, and TM manuscript
354	drafting and editing; SN, YK, MM, TI, and KK: manuscript revision; TI and KK study
355	supervision. All authors have read and approved the final manuscript.
356	
357	

358 Figure Legends

359 **Figure 1**

360 Seropositive rate of total and IgG antibody response in serum specimens collected 361 from mild and severe COVID-19 cases after symptom onset. Plot shows seropositive rate for 362 total and IgG antibody assays per total serum collected from symptom onset. Solid and 363 dashed lines indicate total and IgG antibody assays, respectively. Blue and red lines indicate 364 mild and severe cases, respectively. Ab, antibody. 365 Figure 2 366 Kinetics of total and IgG antibody response between mild and severe cases. Plots 367 show time to sample collection from symptom onset and signal for test sample/signal at cutoff 368 [S/CO] for total and IgG antibodies. (A) Total antibody, (B) IgG antibody. Blue and red lines 369 indicate regression curves of mild and severe cases, respectively. Ab, antibody.

370 Figure 3

371 Comparison between mild and severe cases of total and IgG antibody response for

total antibody (A-C) and IgG antibody (D-E) in serum specimens collected at different

timings from symptom onset. Correlation coefficient calculated using Wilcoxon's rank-sum

374 test. * p < 0.05, ** p < 0.001. Ab, antibody.

Table 1. Clinical characteristics of patients with COVID-19

	All patients (N=130)	Mild (n=98)	Severe (n=32)	<i>p</i> -value
Background characteristi	cs			
Age (years)	45 [37-59]	44 [35-53]	62 [57-69]	< 0.001 **
Time from onset to admission (days)	8 [6-10]	8 [6-10]	8 [6-9]	0.327
Sex				0.002 *
Female	53 (40.8)	47 (48.0)	6 (18.8)	-
Male	77 (59.2)	51 (52.0)	26 (81.3)	-
Smoking history				0.411
Yes	61 (46.9)	43 (43.9)	18 (56.3)	-
No	69 (53.1)	55 (56.1)	14 (43.8)	-
Underlying diseases				
Total	66 (50.8)	39 (39.8)	27 (84.4)	< 0.001 **
Cardiovascular disease	9 (6.9)	6 (6.1)	3 (9.4)	0.688
Hypertension	23 (17.7)	10 (10.2)	13 (40.6)	< 0.001 **
Diabetes	5 (3.8)	1 (1.0)	4 (12.5)	0.013 *
Respiratory disorder	23 (17.7)	14 (14.3)	9 (28.1)	0.107
Malignancy	3 (2.3)	-	3 (9.4)	0.014 *
Clinical features on admis	ssion			
Fever	119 (91.5)	88 (89.8)	31 (96.9)	0.412
Cough	69 (53.1)	50 (51.0)	19 (59.4)	0.541
Malaise	39 (30.0)	32 (32.7)	7 (21.9)	0.371
Diarrhea	31 (23.8)	26 (26.5)	5 (15.6)	0.335
Headache	39 (30.0)	33 (33.7)	6 (18.8)	0.179
Dyspnea	15 (11.5)	-	15 (46.9)	-
Tachypnea	15 (11.5)	-	15 (46.9)	-
Laboratory findings on ac	dmission			
AST (IU/L)	30 [22-43]	27 [20-33]	55 [36-78]	< 0.001**
ALT (IU/L)	31 [18-45]	27 [16-41]	39 [34-66]	< 0.001***
LDH (IU/L)	231 [182-323]	208 [168-267]	376 [304-506]	< 0.001**
Sodium concentration	139 [136-141]	140 [138-142]	136 [134-138]	< 0.001**
C-reactive protein (mg/dL)	1.3 [0.2-4.6]	0.6 [0.1-2.3] 17	9.0 [4.6-13.9]	< 0.001**

White blood cell count	5,152	4,878	6,015	0.007^{*}
(/µL)	[3,808-6,440]	[3,692-6,112]	[3,354-8,355]	0.007
Platelet count (-10^4)	19.5	19.8	22.8	0.658
(×107µL)	[15./-26.6]	[15.9-26.7]	[15.5-23.8]	
Lymphocyte count	1,034 [774-1447]	1,206 [896-1.692]	698 [501-875]	< 0.001***
Neutrophil/lymphocyte	2.8	2.4	7.3	. 0. 001**
ratio	[1.8-4.7]	[1.4-3.5]	[3.8-11.6]	< 0.001
Antibody tests on admissi	on			
Total antibody, positive	76 (58.5)	60 (61.2)	16 (50.0)	0.304
Total antibody (S/CO)	3.71	4.25	1.90	0.152
	[0.2-33.1]	[0.1-32.9]	[0.4-45.6]	1.000
IgG antibody, positive	45 (34.6)	34 (34.7)	11 (34.4)	1.000
IgG antibody (S/CO)	0.1 [0-3 1]	0 [0-3 6]	0.1 [0-2.5]	0.322
Treatment	[* • • • -]	[****]	[*]	
Antibiotics	16 (12.3)	-	16 (50.0)	-
Lopinavir/ritonavir	2 (1.5)	-	2 (6.3)	-
Favipiravir	11 (8.5)	2 (2.0)	9 (28.1)	-
Methylprednisolone	13 (10.0)	-	12 (37.5)	-
Anticoagulant drugs	12 (9.2)	-	12 (37.5)	-
Oxygen therapy	32 (23.6)	-	32 (100)	-
HFNC	14 (10.8)	-	14 (43.8)	-
NPPV	1 (0.8)	-	1 (3.1)	-
IMV	5 (3.8)	-	5 (15.6)	-
Outcome				
Recovery	126 (96.9)	98 (100)	28 (87.5)	-
Death	4 (3.1)	-	4 (12.5)	-

377 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

378 * p < 0.05, ** p < 0.001.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate

dehydrogenase; S/CO, sample/signal at cutoff; HFNC, high-flow nasal cannula; NPPV,

noninvasive positive pressure ventilation; IMV, intermittent mandatory ventilation.

			Positivity rate			S/CO	
		On admission	On discharge	<i>p</i> -value	On admission	On discharge	<i>p</i> -value
	N = 91	54 (59.3%)	90 (98.9%)	< 0.001**	3.7 [0.1 - 33.1]	66.7 [32.3 - 124.3]	< 0.001**
Total Ab	Mild = 65	39 (60.0%)	64 (98.5%)	< 0.001**	4.3 [9.1-32.9]	45.9 [19.1-108]	< 0.001**
	Severe = 26	15 (57.7%)	26 (100.0%)	< 0.001**	1.9 [0.4 - 30.0]	106.6 [60.8 - 172.5]	< 0.001**
	<i>p</i> -value	1.000	1.000		0.805	< 0.001**	
			Positive rate			S/CO	
		On admission	On discharge	p-value	On admission	On discharge	<i>p</i> -value
	Total = 91	34 (37.4%)	81 (89.0%)	< 0.001**	0.1 [0 - 3.1]	8.3 [3.4 - 10.8]	< 0.001**
IgG Ab	Mild = 65	24 (36.9%)	56 (86.2%)	< 0.001**	0.1 [0 - 3.6]	6.2 [2.1 - 5.9]	< 0.001**
8 - 12%	Severe = 26	10 (38.5%)	25 (96.2%)	< 0.001**	0.4 [0 - 2.3]	10.8 [8.7 - 12.6]	< 0.001**
						*	

Table 2. Rate of positive total and IgG antibody assays on admission and discharge

383 Data are presented as n (%) or median [interquartile range], unless otherwise specified.

384 Ab, antibody; S/CO, sample/signal at cutoff

385 * p < 0.05, ** p < 0.001.

Figure 1



Figure 2



Figure 3

